Stockscreener 앱 받기
1.29
5.28%
0.06
시간 외 거래:
1.29
전일 마감가:
$1.23
열려 있는:
$1.23
하루 거래량:
526.64K
Relative Volume:
0.71
시가총액:
$39.82M
수익:
-
순이익/손실:
$-69.00M
주가수익비율:
-0.464
EPS:
-2.78
순현금흐름:
$-55.26M
1주 성능:
-2.63%
1개월 성능:
+16.67%
6개월 성능:
-77.24%
1년 성능:
-78.70%
1일 변동 폭
$1.23
$1.39
1주일 범위
$1.15
$1.39
52주 변동 폭
$1.05
$10.16
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
명칭
Acrivon Therapeutics Inc
전화
617-207-8979
주소
480 ARSENAL WAY, SUITE 100, WATERTOWN
ACRV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
1.29 | 39.82M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.32 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.76 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
544.77 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.03 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-05 | 재개 | Piper Sandler | Overweight |
| 2025-01-31 | 개시 | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | 개시 | JMP Securities | Mkt Outperform |
| 2023-12-15 | 재개 | Jefferies | Buy |
| 2023-10-05 | 개시 | Maxim Group | Buy |
| 2023-06-02 | 개시 | Oppenheimer | Outperform |
| 2023-05-08 | 개시 | BMO Capital Markets | Outperform |
| 2023-04-27 | 개시 | Ladenburg Thalmann | Buy |
| 2023-04-20 | 개시 | H.C. Wainwright | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-12-12 | 개시 | Jefferies | Buy |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
모두보기
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
Acrivon Therapeutics Holds Annual Stockholders Meeting - TipRanks
Analysts Offer Predictions for ACRV FY2026 Earnings - Defense World
Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com
Nuveen Asset Management LLC Sells 12,377 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Northern Trust Corp Has $706,000 Stock Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of “Buy” from Analysts - Defense World
Acrivon Therapeutics: Promising Clinical Developments and Strategic Focus Support Buy Rating - TipRanks
FY2025 EPS Estimate for Acrivon Therapeutics Cut by Analyst - Defense World
Q3 EPS Forecast for Acrivon Therapeutics Boosted by Analyst - Defense World
(ACRV) Investment Analysis and Advice - news.stocktradersdaily.com
Jones Trading Reaffirms Hold Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics (ACRV) Downgraded by Jones Trading | ACRV S - GuruFocus
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch - Yahoo Finance
Oppenheimer Issues Pessimistic Forecast for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World
JonesResearch Downgrades Acrivon Therapeutics (ACRV) to Hold | ACRV Stock News - GuruFocus
Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock By Investing.com - Investing.com South Africa
Acrivon Therapeutics (ACRV) Price Target Lowered by Oppenheimer - GuruFocus
Acrivon Therapeutics (ACRV) Price Target Lowered by Oppenheimer | ACRV Stock News - GuruFocus
Acrivon (ACRV) Advances Clinical Pipeline with Promising Data an - GuruFocus
Oppenheimer Cuts Price Target on Acrivon Therapeutics to $9 From $10, Keeps Outperform Rating - marketscreener.com
Acrivon Therapeutics, Inc.: Promising Clinical Data and Strategic Advancements Justify Buy Rating - TipRanks
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Cantor Fitzgerald maintains Overweight on Acrivon Therapeutics stock - Investing.com
Acrivon Therapeutics (ACRV) Projects Funding Through Mid-2027 | - GuruFocus
Acrivon Therapeutics (ACRV) Price Target Reduced by Oppenheimer - GuruFocus
Optimistic Outlook for Acrivon Therapeutics: Promising ACR-368 Results and Strategic Focus on Endometrial Cancer - TipRanks
Acrivon Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Acrivon Therapeutics (ACRV) Price Target Reduced by Oppenheimer | ACRV Stock News - GuruFocus
Acrivon Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Acrivon Therapeutics Reports Positive ACR-368 Data for Endometrial Cancer and Appoints New Chief Medical Officer - Nasdaq
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Resistant Endometrial Cancer Patients - Stock Titan
Acrivon Therapeutics (ACRV) to Release Earnings on Tuesday - Defense World
(ACRV) Investment Analysis - news.stocktradersdaily.com
Acrivon Therapeutics (NASDAQ:ACRV) Coverage Initiated by Analysts at Piper Sandler - Defense World
Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research
Piper Sandler Initiates Coverage on Acrivon Therapeutics (ACRV) with Overweight Rating | ACRV Stock News - GuruFocus
Piper Sandler sets $6 target for Acrivon stock, rates it Overweight - Investing.com Nigeria
Piper Sandler sets $6 target for Acrivon stock, rates it Overweight By Investing.com - Investing.com South Africa
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Shares Sold by JPMorgan Chase & Co. - Defense World
Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) PT at $21.80 - Defense World
Cantor Fitzgerald Has Positive View of ACRV FY2025 Earnings - Defense World
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Decreases By 19.9% - Defense World
Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million By Investing.com - Investing.com Canada
Major Shareholder Sells Massive Stake in Acrivon Therapeutics! - TipRanks
Acrivon Therapeutics’ major shareholder sells shares worth $1.02 million - Investing.com
Acrivon Therapeutics Inc (ACRV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Acrivon Therapeutics Inc 주식 (ACRV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% Owner |
May 01 '25 |
Sale |
1.34 |
298,886 |
400,507 |
3,104,139 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 25 '25 |
Sale |
1.95 |
1,054,669 |
2,056,605 |
4,306,189 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 29 '25 |
Sale |
1.41 |
250,000 |
352,500 |
3,840,906 |
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 28 '25 |
Sale |
1.56 |
215,283 |
335,841 |
4,090,906 |
1.35%
0.81%
자본화:
|
볼륨(24시간):